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Abstract
This review is an attempt to summarize our knowledge about taurine bromamine (TauBr) properties, its role in
innate immunity and its therapeutic potential.
TauBr and taurine chloramine (TauCl) are major haloamines generated by eosinophils and neutrophils at a site of
inflammation. Both haloamines share anti-inflammatory and anti-oxidant properties. TauBr, similarly to TauCl,
decreases the production of proinflammatory mediators. Their anti-inflammatory and anti-oxidant activities are
enhanced by their ability to induce the expression of heme oxygenase-1 (HO-1). TauCl is more stable than TauBr.
On the other hand, only TauBr was found to be highly membrane-permeable showing stronger microbicidal activ-
ity than TauCl.
In the light of the anti-inflammatory and antimicrobial properties of TauBr we discuss its therapeutic potential in
local treatment of inflammation, especially acne vulgaris, the most common inflammatory skin disorder. TauBr, at
non-cytotoxic concentrations, is able to kill Propionibacterium acnes, the skin bacteria involved in pathogenesis of
acne vulgaris.
As topical antibiotics used in the therapy of acne are associated with the emergence of resistant bacteria, topical
TauBr seems to be a good candidate for an alternative therapy.
Recently, in a double blind trial, the efficacy of TauBr was compared with the efficacy of clindamycin, one of the
most common topical antibiotics used in acne therapy. Comparable reduction of acne lesions was observed in the
TauBr and clindamycin groups of patients with mild and moderate inflammatory facial acne vulgaris. We conclude
that this pilot study supports our concept that TauBr can be used as a topical agent in the treatment of acne vul-
garis, especially in patients who have already developed antibiotic resistance. Further studies are necessary to sub-
stantiate the more extended use of TauBr as an anti-inflammatory and anti-oxidant agent in human medicine.
Introduction
Activated neutrophils and eosinophils generate a variety
of reactive oxygen species (ROS). Hypochlorous acid
(HOCl) and hypobromous acid (HOBr) are the major
reactive oxidants generated by these cells at sites of
inflammation. Both agents, components of the human
innate immune system, exert strong microbicidal activ-
ity, but their excessive production leads to tissue
damage [1,2]. Taurine, a sulfur-containing amino acid
(2-aminoethane sulphonic acid), is the most abundant
free amino acid in the leukocyte cytosol (30 mM) and is
the major scavenger for both hypohalous acids, HOCl
and HOBr [3]. The products of the reaction between
t a u r i n ea n dH O B ro rH O C la r et a u r i n eb r o m a m i n e
(TauBr, N-bromotaurine) or taurine chloramine (TauCl,
N-chlorotaurine), respectively [4,5].
TauCl is considered the major haloamine produced
in vivo by neutrophils. A large number of reports have
shown a key role of TauCl in innate immunity and sug-
gest its use in therapy of various topical infections as
well as chronic inflammatory diseases [6]. In contrast,
TauBr has attracted little attention because the extracel-
lular concentration of bromide is at least 1,000-fold
lower than that of chloride [2]. However, brominating
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antimicrobial agents in vitro [7,8].
In the present paper we discuss data showing anti-
inflammatory and microbicidal properties of TauBr con-
firming its therapeutic potential. Finally, we demonstrate
that TauBr may be a good candidate for a local treat-
ment of skin inflammatory diseases, especially for acne
vulgaris, a hypothesis supported by our recent pilot
clinical study [9].
In vivo generation of TauBr
Neutrophil myeloperoxidase (MPO) and eosinophil per-
oxidase (EPO) use hydrogen peroxide (H2O2)t oo x i d i z e
halides and thiocyanate to their respective hypohalous
acids. At plasma concentrations of halide (100 mM
chloride; 20-100 μM bromide; <1 μM iodide) eosinophil
peroxidase preferentially oxidizes bromide (Br
-)t op r o -
duce hypobromous acid, HOBr.
Br
- +H 2O2 +H
+ ® HOBr + H2O
Recent studies have shown that HOBr may also be
generated by the MPO-halide system of neutrophils.
HOCl + Br
- ® HOBr + Cl
-
HOCl and hypochlorite ion (OCl
-) are therefore
mainly produced by MPO, while HOBr and hypobro-
mite (OBr
-) are produced by both EPO and MPO [1,2].
HOBr, at physiological pH, reacts readily with amine
compounds to form secondary oxidants such as mono-
bromamines, di-bromamines and amino acid-derived
aldehydes. These brominating agents, and HOBr in par-
ticular, contribute to innate immunity by virtue of hav-
ing the ability to kill micro organisms but they may also
damage host tissues and contribute to inflammatory
tissue injury [10,11].
As taurine is the most abundant free amino acid in
the leukocyte cytosol, TauBr is the major bromamine
generated in vivo by eosinophil or neutrophil peroxidase.
It is commonly accepted that taurine is the primary sca-
venger of overproduced or dislocated HOCl and HOBr.
TauBr and TauCl are relatively long lived oxidants, and
are less toxic than the corresponding hypohalous acids
[4,5,12]. TauBr is therefore believed to protect cells
against damage by HOBr [1,2]. However, in contrast to
the large body of evidence demonstrating the role of
TauCl in innate immunity, much less is known about
microbicidal properties of TauBr [11-13].
In vitro synthesis and detection of TauBr
To determine the function of TauBr, taurine
mono-bromamine has been synthesized in vitro and used
in a variety of experimental systems [8,10]. In our studies
we have used the following protocol for synthesis and
detection of TauBr in vitro.
TauBr preparation: HOBr/OBr
- was generated by mix-
ing equimolar amounts of HOCl
ˉ and NaBr
ˉ.T h e n ,t h e
product of this reaction was mixed with taurine. The
mono-bromamine was obtained with a 10-fold excess of
amine over the amount of HOBr/OBr
-. Each preparation
of TauBr was monitored by UV absorption spectra
(l=200 - 400 nm) to assure the authenticity of mono-
bromamine (TauBr) (Fig. 1). Taurine bromamines
(TauBr, TauBr2) have absorption spectra similar to
those of chloramines, but shifted 36 nm towards longer
wavelengths. The concentration of synthesized TauBr
(taurine mono-bromamine) was determined using the
molar extinction coefficient 415 M
-1 cm
-1 at A288 [1,8].
TauBr and immune system
Our current knowledge concerning the physiological
functions of TauBr is based mainly on experimental
models investigating the effects of exogenous TauBr
[9,10]. In studies with isolated leukocytes, evidence for
the formation of endogenous brominating agents was
obtained, but long lived bromamines were not detected
in the medium. One may speculate that the reduction of
HOBr
- and bromamines by H2O2
, produced by activated
leukocytes, may account for these results. Indeed, in vitro
studies from a number of laboratories show that TauBr,
similarly to HOBr/Br
-,i sr e d u c e db yH 2O2,r e s u l t i n gi n
the loss of oxidizing and brominating activity [2,10].
TauBr + H2O2 = Tau + H
+ +B r
– +O 2.
The ability of TauBr, to react and inactivate H2O2 [1]
probably contributes to the reported “antioxidant” and
anti-inflammatory properties of this compound. In addi-
tion, both TauBr and TauCl can induce the synthesis of
heme oxygenase-1 (HO-1) [14], a stress-inducible
enzyme, which also has antioxidant and anti-inflamma-
tory capacity. TauBr, similarly to TauCl, is a powerful
regulator of inflammation [10,15-17]. Both taurine
Figure 1 The UV absorption spectrum of taurine mono-bromamine
(TauBr) lmax = 288 nm.
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pressing the production of such mediators as nitric
oxide, PGE2,T N F - a, IL-6, IL-8, IL-12 and chemokines
in both rodent and human leukocytes [10,15,18,19]. Stu-
dies investigating the mechanisms of action of TauCl
have shown that it inhibits the activation of NF-B, a
potent signal transducer for inflammatory cytokines, by
oxidation of IkB-a at Met
45, and recent studies have
extended these findings to TauBr [16].
While the anti-inflammatory properties of endogen-
ous TauCl and TauBr are well established, it is less
clear whether these compounds also contribute to
microbial killing. Our data (Fig. 2) show that TauBr
has strong microbicidal activity comparable to HOCl
at micro molar concentrations, while at these concen-
trations TauCl did not kill bacteria [8]. These results
are in agreement with the studies of Gaut et al. [17],
who found that addition of low concentration of bro-
mide (1μMB r
-) markedly increased bactericidal activity
of the complete myeloperoxidase-H2O2–halide system.
Therefore, one may speculate that physiological varia-
tions in Br
- concentration may amplify neutrophil bac-
tericidal activity, by driving formation of HOBr and
TauBr.
Importantly, TauBr, at bactericidal concentrations
(< 200 μM) does not exert cytotoxic activity [10]. More-
over, it has been shown that TauBr at physiological con-
centrations is able to kill the schistosomula of
Schistosoma mansoni confirming its role in the defence
against parasites [11]. The contribution of chlorinating
and brominating oxidants in pathogen killing and tissue
injury will also depend on their interactions with other
biologically active agents present at a site of inflamma-
tion. For example, TauBr may be neutralised by H2O2,
as mentioned above [2,10].
Therapeutic perspectives for TauBr
Is TauBr a good candidate for treatment of skin
inflammatory diseases? A number of clinical studies
h a v es h o w nt h a tT a u C lm a yb eu s e f u lf o rt h et r e a t -
ment of various topical infections due to its combina-
tion of microbicidal and anti-inflammatory properties.
However, in the majority of clinical trials TauCl was
used at very high, non-physiological concentrations
[6,20]. Much less is known concerning the therapeutic
potential of TauBr.
As discussed above, we have shown that TauBr in
vitro has much stronger bactericidal activity than TauCl,
with a potency which approaches that of HOCl, the
most potent bactericidal agent of MPO-halide system
[8]. Interestingly, susceptibility of Propionibacterium
acnes (P.acnes) to TauBr appeared to be significantly
higher than that of Staphylococcus epidermidis (S.epider-
midis) (Fig. 3). Both species belong to the bacterial flora
of the skin.
Importantly, TauBr killed all tested bacteria at non-
cytotoxic, anti-inflammatory concentrations. From a
clinical point of view these data strongly suggest that
the therapeutic potential of TauBr may be similar or
even better than that of TauCl.
Based on these studies of the biological properties and
functions of taurine haloamines and on our studies
demonstrating the selective antimicrobial activity of
TauBr, we have examined the clinical efficacy of TauBr
in the topical treatment of acne vulgaris, an inflamma-
tory skin disease with bacterial etiology [9].
Acne vulgaris is the most common inflammatory
skin disorder in adolescents and young adults [21].
Pathogenesis of acne is complex, involving multiple
abnormalities of the pilosebaceous unit, including
hyperkeratinisation, sebum production, bacterial prolif-
eration and inflammation. One of the pathogenic fac-
tors of acne is P. acnes[22,23]. Topical antibacterial
agents are an essential element of the armamentarium
for the treatment of acne vulgaris [24,25]. As P. acnes,
Figure 2 Bactericidal activity of TauBr, TauCl and HOCl against E.
coli [10].
Figure 3 Susceptibility of P. acnes and S. epidermidis to TauBr.
Data are expressed as MBC values (the concentrations of TauBr that
cause 100% inhibition of bacteria growth) [9].
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sitive to TauBr, we hypothesized that TauBr may be a
good candidate for the topical therapy for acne vul-
garis, without the risk of inducing bacterial resistance
[26,27].
In a double blind pilot study, the efficacy and safety of
TauBr cream was evaluated [9]. Clindamycin gel, one of
the most common topical agents in the treatment of
acne vulgaris, was used as a control. Forty patients with
mild to moderate inflammatory facial acne vulgaris were
randomly treated with either TauBr or clindamycin.
After 6 weeks, both treatments produced comparable
beneficial results. More than 90% of patients improved
clinically with a similar reduction in number of acne
lesions (~65%), and with no side effects. Therefore, the
results from this clinical pilot are in agreement with
previous in vitro data and strongly suggest that TauBr
could be considered a new therapeutic option in inflam-
matory acne.
Conclusions
TauBr, the major bromamine generated at the site of
inflammation, exerts both anti-inflammatory and anti-
microbial properties, at non-cytotoxic concentrations. In
addition, its ability to reduce other oxidants (e.g. H2O2)
stresses the active role of TauBr in innate immunity.
These biological properties make TauBr a good candi-
date for a topical treatment of inflammatory diseases.
Further clinical investigations will be required to deter-
mine whether TauBr used in monotherapy or in combi-
nation with other agents may be a useful alternative
treatment for acne vulgaris.
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